Uncover insights from pre-clinical and clinical research through commercialization
Early R&D
Assess viability of new programs by studying disease burden
Clinical & translational
Discover new biomarkers, understand patient journey, & inform trial design
Commercial
Identify newly diagnosed patients & engage their clinicians
Real-world outcomes
Understand real-world treatment patterns and efficacy outcomes
Data-informed decision making
Patient identification
Identify newly-diagnosed patients who meet your criteria and engage their clinicians through our patient identification alert tool or Sponsored Testing Program, designed specifically for biopharma companies. Receive notifications on cohorts-of-interest.
Target validation
Understand real-world characteristics of your patient population with a genetics-based cohort builder. View data at the variant level to quickly understand disease prevalence, geographic distribution and more.
Clinicogenomics
Uncover genotype-phenotype associations across large populations. Query large volumes of patient-level data in genetically-defined cohorts, and combine with clinical data sources.
Natural history studies
Invitae’s solutions for biopharma companies can help you deepen understanding of disease with patient-consented, real-world clinical data. Access a single source of research-ready medical records data from all healthcare institutions that a patient has visited.
Clinical trial recruitment
Leverage our extensive global network to inform patients and their clinicians of relevant clinical trials to accelerate trial enrollment.
Lab services
High-quality NGS services ranging from data generation for basic research to clinical testing for highly regulated studies at various stages in clinical trials. Accelerate clinical research with tumor-informed ctDNA MRD assay to validate efficacy of therapy and monitor response.
Powered by Invitae's medical-grade genetic testing
Making the highest-quality genetic testing accessible to patients is at the core of Invitae's mission. At Invitae, we also believe that patients own and control their data, and that data is more valuable when shared. With patient-consented genetic and clinical data, biopharma gains tools necessary to translate promising genetic research into new therapies for patients.
5,000,000+
patients served
430,000+
longitudinal clinical data points
100+
biopharma partner programs
Data use transparency and impact
In 2023, Invitae released our second Data use transparency and impact report, which lists all the ways de-identified data from Invitae patients were repurposed in 2022 to advance the field of genetics research.
We chose to partner with Invitae because of the uniqueness of scale and depth of the dataset on affected populations. Patients with severe and highly penetrant dominant disorders are not represented in general population studies, making it near impossible to find anywhere except a disease-focused cohort like Invitae. These rich data sources will continue to offer researchers a mechanism to get a much deeper understanding of the genetic variation and will help inform our decision-making process.”
- Sun-Gou Ji, VP of Computational Genetics, BridgeBio